Cancer immunotherapy targeting neoantigens derived from tumor-specific gene mutations

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Cancer immunotherapies targeting tumor-associated antigens (TAAs) have yielded limited clinical success.
• TAAs are derived from wild-type proteins and are not always tumor-specific.

Purpose of the Study:

• To review the clinical significance of tumor-specific neoantigens (TSNAs).
• To discuss the potential of TSNAs in personalized cancer immunotherapy.

Main Methods:

• Review of recent advancements in next-generation sequencing and bioinformatics.
• Analysis of literature on neoantigens derived from tumor-specific genetic alterations (mutations, insertions, deletions).

Main Results:

• Tumor-specific neoantigens are recognized as foreign by the host immune system, unlike TAAs.
• TSNAs exhibit higher immunogenicity, potentially leading to more effective anti-tumor immune responses.

Conclusions:

• TSNAs hold significant promise for developing personalized cancer immunotherapies.
• Targeting TSNAs may offer a more effective strategy for controlling tumor burden compared to TAAs.